Kimberly L. Blackwell, MD | Authors

How Can We Optimize Treatment of HER2-Positive Metastatic Breast Cancer?

March 15, 2013

Third, how much do we really know about de novo and acquired resistance to trastuzumab and lapatinib? There are several possible clinical relevant mechanisms of trastuzumab resistance, including crosstalk with other receptors, amplification of the PI3K/AKT pathway, alteration of the trastuzumab binding domain, and loss of HER2 expression.

Breast Cancer at ASCO: Latest Trial Results and Emerging Therapies

June 21, 2012

CancerNetwork and the journal ONCOLOGY present an exclusive interview with Dr. Kimberly Blackwell, Duke Cancer Institute, who discusses some of the most important information to come out of this year’s meeting and talks about the future of breast cancer research.